Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has entered into a licensing agreement with Nobelpharma, pursuant to which, Eisai granted Norbelpharma the exclusive right to develop and commercialize Gliadel wafer in Japan, while retaining an option right to obtain the exclusive commercialization right of Gliadel wafer in Japan once the new drug application has been filed for approval.
Subscribe to our email newsletter
According to Eisai, Gliadel wafer is the only FDA-approved chemotherapeutic implant for use during surgical procedures for malignant glioma. Gliadel wafer has been approved in 18 countries worldwide, primarily in North America, Europe, and Southeast Asia.
Early approval of Gliadel wafer has been requested in Japan and it was taken as a subject in 2008 by the Investigational Committee for Usage of Unapproved Drugs, a body established by the Ministry of Health Labour and Welfare.
Eisai expects that the development of Gliadel wafer by Nobelpharma will bring a new treatment option to patients with malignant glioma in Japan as early as possible.